{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:17:08Z","timestamp":1791343028654,"version":"4.3.1"},"reference-count":138,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections. Compared with the product previously used, it has a stronger binding capacity to RSV F protein and a high affinity for FcRn (neonatal receptor for the Fc fragment of IgG), which extends its lifespan. Nirsevimab has been shown to be highly effective in reducing hospitalization rates of RSV infections but a large or unknown number of treated subjects have been excluded in clinical and post-marketing studies. However, analysis of these studies cannot exclude that, in rare cases, nirsevimab facilitates and worsens RSV infection (or other respiratory infections). This could be attributable to antibody-dependent enhancement (ADE) which has been observed with RSV F protein antibodies in inactivated vaccine trials. This risk has been incompletely assessed in pre-clinical and clinical trials (incomplete exploration of nirsevimab effector functions and pharmacokinetics). ADE by disruption of the immune system (not studied and due to FcRn binding) could explain why there is no reduction in all-cause hospital admissions in treated age groups. Given the high price of nirsevimab, the cost-effectiveness of mass immunization campaigns may therefore be debated from an economic as well as a scientific point of view.<\/jats:p>","DOI":"10.3390\/cimb46090617","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:23:04Z","timestamp":1726737784000},"page":"10369-10395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of Beyfortus\u00ae (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8391-7989","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Banoun","sequence":"first","affiliation":[{"name":"Independent Researcher, 13001 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rocca, A., Biagi, C., Scarpini, S., Dondi, A., Vandini, S., Pierantoni, L., and Lanari, M. (2021). Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073703"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/cdli.1.6.670-677.1994","article-title":"Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants","volume":"1","author":"Osiowy","year":"1994","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Acevedo, O.A., D\u00edaz, F.E., Beals, T.E., Benavente, F.M., Soto, J.A., Escobar-Vera, J., Gonz\u00e1lez, P.A., and Kalergis, A.M. (2019). Contribution of Fc\u03b3 Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00075"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2147\/IDR.S379660","article-title":"New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus","volume":"16","author":"Bueno","year":"2023","journal-title":"Infect. Drug. Resist."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rigter, A., Widjaja, I., Versantvoort, H., Coenjaerts, F.E.J., van Roosmalen, M., Leenhouts, K., Rottier, P.J.M., Haijema, B.J., and de Haan, C.A.M. (2013). A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071072"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/infdis\/jiac481","article-title":"Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV-seropositive children 12\u201323 months of age","volume":"227","author":"Epalza","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/infdis\/jiac407","article-title":"Phase 1\/2a safety and immunogenicity of an adenovirus 26 vector respiratory syncytial virus (RSV) vaccine encoding prefusion F in adults 18\u201350 years and RSV-seropositive children 12\u201324 months","volume":"227","author":"Stuart","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DeltaNS2\/Delta1313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV\/deltaNS2\/delta1313\/I1314L and RSV\/276 in RSV-seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"(2024, April 25). European Union Risk Management Plan (EU RMP) for Beyfortus\u00ae (Nirsevimab) 3 May 2021. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/beyfortus-epar-risk-management-plan_en.pdf."},{"key":"ref_14","unstructured":"(2024, April 25). Article 14(9) EC-726\/2004 of the European Parliament and of the Council of 31 March 2004 Laying Down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Medicines Agency. Available online: http:\/\/data.europa.eu\/eli\/reg\/2004\/726\/oj."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","article-title":"Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009\u20132019: A Study of the National (Nationwide) Inpatient Sample","volume":"226","author":"Suh","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(12)61901-1","article-title":"Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: A systematic analysis","volume":"381","author":"Nair","year":"2013","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","article-title":"Burden of Respiratory Syncytial Virus in the European Union: Estimation of RSV-associated hospitalizations in children under 5 years","volume":"228","author":"Spreeuwenberg","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_18","unstructured":"(2024, April 22). Bulletin Infections Respiratoires Aigu\u00ebs, Publi\u00e9 le 17 Avril 2024. Available online: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-et-infections-respiratoires\/grippe\/documents\/bulletin-national\/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bilan-de-la-saison-2023-2024."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e247125","DOI":"10.1001\/jamanetworkopen.2024.7125","article-title":"Respiratory Syncytial Virus Hospital-Based Burden of Disease in Children Younger Than 5 Years, 2015\u20132022","volume":"7","author":"Suss","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01714","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity","volume":"386","author":"Domachowske","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials","volume":"7","author":"Muller","year":"2023","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"(2024, April 15). EMA-EPAR Beyfortus-Nirsevimab. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus#assessment-history,."},{"key":"ref_28","unstructured":"(2024, April 22). HAS Nirsevimab Transparency Committee 19 July 2023. Available online: https:\/\/www.has-sante.fr\/plugins\/ModuleXitiKLEE\/types\/FileDocument\/doXiti.jsp?id=p_3476336."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41372-024-01970-y","article-title":"Does nirsevimab prevent lower respiratory infections caused by respiratory syncytial virus?","volume":"44","author":"Sullivan","year":"2024","journal-title":"J. Perinatol."},{"key":"ref_30","unstructured":"(2024, April 13). FDA Biologics License Application (BLA) 761328 Nirsevimab Antimicrobial Drugs Advisory Committee Meeting June 8, 2023 Division of Antivirals. Office of Infectious Diseases Center for Drug Evaluation and Research, Available online: https:\/\/www.fda.gov\/media\/169322\/download."},{"key":"ref_31","unstructured":"(2024, April 15). EudraVigilance European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/fr\/eudravigilance.html."},{"key":"ref_32","unstructured":"(2024, April 22). Pharmacovigilance d\u2019\u00cele de France, Campagne D\u2019immunisation Contre le VRS-Beyfortus, 31 Jaanvier 2024. Available online: https:\/\/www.pharmacovigilance-iledefrance.fr\/d%C3%A9tails-dune-br%C3%A8ve\/campagne-dimmunisation-contre-le-vrs-beyfortus-nirs%C3%A9vimab."},{"key":"ref_33","unstructured":"US-FDA (2024, April 15). FDA Approves New Drug to Prevent RSV in Babies and Toddlers, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_35","first-page":"264","article-title":"Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2023\u20132024 season","volume":"99","year":"2023","journal-title":"An. Pediatr\u00eda"},{"key":"ref_36","unstructured":"(2024, May 17). New Immunisation to Protect Newborns and Young Children against Bronchiolitis. The Luxembourg Governement Press Release. 22 September 2023. Available online: https:\/\/gouvernement.lu\/en\/actualites\/toutes_actualites\/communiques\/2023\/09-septembre\/22-immunisation-bronchiolite-nourrissons.html."},{"key":"ref_37","unstructured":"CDC (2024, April 15). Nirsevimab Coverage, Children 0 to 19 Months, United States. Data are Current through 29 February 2024, Available online: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/rsvvaxview\/nirsevimab-coverage-children-0-19months.html."},{"key":"ref_38","unstructured":"(2024, April 15). RSV-NET Interactive Dashboard. CDC, Available online: https:\/\/www.cdc.gov\/rsv\/research\/rsv-net\/dashboard.html."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus\u2013Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season\u2014New Vaccine Surveillance Network, October 2023\u2013February 2024","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/0019-5154.177773","article-title":"Methodology Series Module 2: Case-control Studies","volume":"61","author":"Setia","year":"2016","journal-title":"Indian J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","article-title":"Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg","volume":"29","author":"Ernst","year":"2024","journal-title":"Eurosurveillance"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMoa2314885","article-title":"Nirsevimab and Hospitalization for RSV Bronchiolitis","volume":"391","author":"Assad","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_43","unstructured":"EPI-PHARE (2024, June 03). Utilisation du Nirs\u00e9vimab (Beyfortus\u00ae) en Ville en France lors de la Premi\u00e8re Campagne de Pr\u00e9vention (Saison 2023\/2024) 8 April 2024. Available online: https:\/\/www.epi-phare.fr\/rapports-detudes-et-publications\/utilisation-beyfortus\/."},{"key":"ref_44","unstructured":"(2024, May 01). Bronchiolite: Bilan de la Surveillance Hivernale 2022\u20132023, Sant\u00e9 Publique France. 19 July 2023. Available online: https:\/\/www.santepubliquefrance.fr\/les-actualites\/2023\/bronchiolite-bilan-de-la-surveillance-hivernale-2022-2023."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e13311","DOI":"10.1111\/irv.13311","article-title":"Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in pediatric intensive care units in France, September 2023\u2013January 2024","volume":"18","author":"Paireau","year":"2024","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.idnow.2022.06.003","article-title":"Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020\u20132021 and 2021\u20132022 seasons","volume":"52","author":"Vaux","year":"2022","journal-title":"Infect. Dis. Now"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1002\/ppul.25644","article-title":"Impact of COVID-19 social distancing on viral infection in France: A delayed outbreak of RSV","volume":"56","author":"Delestrain","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_48","unstructured":"(2024, May 12). International Classification of Diseases. Tenth Revision. International Statistical Classification of Diseases and Related Health Problems 10th Revision Latest Version 2019. WHO. Available online: https:\/\/icd.who.int\/browse10\/2019\/en."},{"key":"ref_49","unstructured":"(2024, April 15). La Sanidad P\u00fablica Paga 209 Euros por Cada Vacuna Infantil Contra la Bronquiolitis, Civio. 30 October 2023. Available online: https:\/\/civio.es\/medicamentalia\/2023\/10\/30\/nirsevimab-beyfortus-precio-virus-respiratorio-sincitial\/."},{"key":"ref_50","unstructured":"(2024, February 10). Servicio Andaluz de Salud, El Distrito Serran\u00eda Recibe un Reconocimiento por la Cobertura de la Vacuna Combinada Frente a Difteria, T\u00e9tanos, Tosferina y Poliomielitis 30 January 2024. Available online: https:\/\/www.sspa.juntadeandalucia.es\/servicioandaluzdesalud\/todas-noticia\/el-distrito-serrania-recibe-un-reconocimiento-por-la-cobertura-de-la-vacuna-combinada-frente."},{"key":"ref_51","unstructured":"(2024, April 23). Administradas 452.000 Vacunas por Virus Respiratorios, Ondacero.es. 8 April 2024. Available online: https:\/\/www.ondacero.es\/emisoras\/asturias\/noticias\/administradas-452000-vacunas-virus-respiratorios_202404086613a4ec099903000111cfb3.html."},{"key":"ref_52","unstructured":"(2024, April 23). La Comunidad de Madrid Reduce un 90% los Ingresos Hospitalarios de Menores de un A\u00f1o Tras Incorporar la Vacuna Contra la Bronquiolitis. Communiqu\u00e9 de Presse de la Comunidad de Madrid. 16 April 2024. Available online: https:\/\/www.comunidad.madrid\/notas-prensa\/2024\/04\/16\/comunidad-madrid-reduce-90-ingresos-hospitalarios-menores-ano-incorporar-vacuna-bronquiolitis."},{"key":"ref_53","unstructured":"(2024, April 23). Ministerio de Ciencia, Innovacion y Universidades, Gobierno de Espana, Informes Semanales de Vigilancia Centinela de IRAs y de IRAG: Gripe, COVID-19 y Otros Virus Respiratorios. Available online: https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Paginas\/VIGILANCIA-CENTINELA-DE-INFECCION-RESPIRATORIA-AGUDA.aspx."},{"key":"ref_54","unstructured":"(2024, April 23). Follow-Up Report on Immunization with Nirsevimab in Galicia Direcci\u00f3n Xeral de Sa\u00fade P\u00fablica Data up to Week 13. 2024 (31 March 2024). Available online: https:\/\/www.nirsegal.es\/en."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"P817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: Initial results of a population-based longitudinal study","volume":"24","author":"Mallah","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","unstructured":"(2024, May 10). Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization (NIRSE-GAL), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06180993."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Ezpeleta, G., Navascu\u00e9s, A., Viguria, N., Herranz-Aguirre, M., Belloc, S.E.J., Ballester, J.G., Muruz\u00e1bal, J.C., Garc\u00eda-Cenoz, M., Trobajo-Sanmart\u00edn, C., and Echeverria, A. (2024). Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines, 12.","DOI":"10.3390\/vaccines12040383"},{"key":"ref_58","unstructured":"(2024, May 01). Boletin de Salud Publica de Navarra, n\u00b0126. September 2023. Available online: http:\/\/www.navarra.es\/home_es\/Gobierno+de+Navarra\/Organigrama\/Los+departamentos\/Salud\/Organigrama\/Estructura+Organica\/Instituto+Navarro+de+Salud+Publica\/Publicaciones\/Publicaciones+profesionales\/Epidemiologia\/Boletin+ISP.htm."},{"key":"ref_59","unstructured":"(2023, August 30). DGS-URGENT 9. 24 August 2023. DGS-URGENT N\u00b02023_14. Prevention Medicamenteuse des Bronchiolites A VRS A Partir De Septembre, Available online: https:\/\/sante.gouv.fr\/IMG\/pdf\/dgs-urgent_2023-14_-_traitement_preventif_vrs.pdf."},{"key":"ref_60","unstructured":"DREES (2024, April 23). La Naissance: Caract\u00e9ristiques des Accouchements, Available online: https:\/\/drees.solidarites-sante.gouv.fr\/sites\/default\/files\/2021-07\/Fiche%2024%20-%20La%20naissance%20-%20caract%C3%A9ristiques%20des%20accouchements.pdf."},{"key":"ref_61","unstructured":"(2024, April 30). INSEE D\u00e9c\u00e8s et Mortalit\u00e9. Available online: https:\/\/www.insee.fr\/fr\/statistiques\/7767420?sommaire=7764286."},{"key":"ref_62","unstructured":"(2024, April 30). Nombre Mensuel de Naissances (de Janvier 2015 \u00e0 Octobre 2023). Available online: https:\/\/www.insee.fr\/fr\/statistiques\/7758827?sommaire=5348638."},{"key":"ref_63","unstructured":"(2024, June 03). Journal Officiel, France. 231 December 2023. Available online: https:\/\/www.senat.fr\/questions\/jopdf\/2023\/2023-12-21_seq_20230050_0001_p000.pdf."},{"key":"ref_64","unstructured":"DGS Beyfortus (2024, January 12). Fin de la Campagne de Distribution. 26 December 2023. Reference MARS n\u00b0 2023-23. Limited Diffusion, Available online: https:\/\/sante.gouv.fr\/professionnels\/article\/dgs-urgent."},{"key":"ref_65","unstructured":"(2024, August 06). Cour des Comptes 06.05.2024 La Politique de P\u00e9rinatalit\u00e9. Available online: https:\/\/www.ccomptes.fr\/fr\/publications\/la-politique-de-perinatalite."},{"key":"ref_66","first-page":"CD009417","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","volume":"8","author":"Sanders","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection","volume":"13","author":"Resch","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Kiener","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Qi, T., and Cao, Y. (2021). In Translation: FcRn across the Therapeutic Spectrum. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063048"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.20020400","article-title":"Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung","volume":"196","author":"Spiekermann","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Pyzik, M., Sand, K.M.K., Hubbard, J.J., Andersen, J.T., Sandlie, I., and Blumberg, R.S. (2019). The Neonatal Fc Receptor (FcRn): A Misnomer?. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01540"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","article-title":"Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier","volume":"81","author":"Schlachetzki","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"L616","DOI":"10.1152\/ajplung.00121.2004","article-title":"Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers","volume":"287","author":"Kim","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/wmts.17","article-title":"Function of Proton Channels in Lung Epithelia","volume":"1","author":"Fischer","year":"2012","journal-title":"Wiley Interdiscip. Rev. Membr. Transp. Signal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15973","DOI":"10.1073\/pnas.1311999110","article-title":"Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways","volume":"110","author":"Garland","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcf.2013.12.006","article-title":"Neonates with cystic fibrosis have a reduced nasal liquid pH: A small pilot study","volume":"13","author":"Beer","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41467-017-00532-5","article-title":"Airway surface liquid pH is not acidic in children with cystic fibrosis","volume":"8","author":"Schultz","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/19420862.2019.1602459","article-title":"Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis","volume":"11","author":"Challa","year":"2019","journal-title":"mAbs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nbt.1742","article-title":"Efficient mucosal vaccination mediated by the neonatal Fc receptor","volume":"29","author":"Ye","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cell.2019.04.035","article-title":"Human Neonatal Fc Receptor Is the Cellular Uncoating Receptor for Enterovirus, B","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1073\/pnas.1817341116","article-title":"The neonatal Fc receptor is a pan-echovirus receptor","volume":"116","author":"Morosky","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.4049\/jimmunol.130.6.2915","article-title":"Infection of a macrophage-like cell line, P388D1 with reovirus; effects of immune ascitic fluids and monoclonal antibodies on neutralization and on enhancement of viral growth","volume":"130","author":"Burstin","year":"1983","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2353\/ajpath.2006.050482","article-title":"Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis","volume":"168","author":"Maidji","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Gupta, S., Gach, J.S., Becerra, J.C., Phan, T.B., Pudney, J., Moldoveanu, Z., Joseph, S.B., Landucci, G., Supnet, M.J., and Ping, L.-H. (2013). The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog., 9, Erratum in PLoS Pathog. 2013, 9.","DOI":"10.1371\/annotation\/31430955-703b-484a-96eb-e180f917d683"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/infdis\/jiu300","article-title":"Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted\/founder strain number after rectal challenge","volume":"211","author":"Gupta","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imr.12367","article-title":"Fc receptors in antibody-dependent enhancement of viral infections","volume":"268","author":"Taylor","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_91","first-page":"246","article-title":"Measles and Antibody-Dependent Enhancement (ADE): History and Mechanisms","volume":"7","author":"Banoun","year":"2022","journal-title":"Explor. Res. Hypothesis Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"Tirado","year":"2003","journal-title":"Viral Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2016.05.003","article-title":"RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors","volume":"132","author":"Luytjes","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3345\/kjp.2019.00402","article-title":"Positive association of breastfeeding on respiratory syncytial virus infection in hospitalized infants: A multicenter retrospective study","volume":"63","author":"Jang","year":"2020","journal-title":"Clin. Exp. Pediatr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijid.2022.10.039","article-title":"High seroprevalence of antibodies against human respiratory syncytial virus and evidence of respiratory syncytial virus reinfection in young children in Thailand","volume":"125","author":"Pasittungkul","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1165\/ajrcmb.23.5.3771","article-title":"Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages","volume":"23","author":"Barr","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eabj7843","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.ai.2021.08.003","article-title":"Antibody dependent enhancement: Unavoidable problems in vaccine development","volume":"151","author":"Xu","year":"2021","journal-title":"Adv. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1128\/JVI.00649-14","article-title":"Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q","volume":"88","author":"Pozzuto","year":"2014","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041309","article-title":"Human Antibodies for Viral Infections","volume":"40","author":"Crowe","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41385-018-0129-x","article-title":"Fc\u03b3RIII stimulation breaks the tolerance of human nasal epithelial cells to bacteria through cross-talk with TLR4","volume":"12","author":"Golebski","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.4049\/jimmunol.132.3.1529","article-title":"Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies","volume":"132","author":"Halstead","year":"1984","journal-title":"J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","article-title":"Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis","volume":"152","author":"Thomas","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1099\/0022-1317-74-8-1527","article-title":"Restricted replication of respiratory syncytial virus in human alveolar macrophages","volume":"74","author":"Cirino","year":"1993","journal-title":"J. Gen. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1159\/000446824","article-title":"Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons","volume":"8","author":"Makris","year":"2016","journal-title":"J. Innate Immun."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zheng, J., Wang, X., Yang, P., and Zhao, D. (2022). Alveolar macrophages and airway hyperresponsiveness associated with respiratory syncytial virus infection. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1012048"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Vanderven, H.A., and Kent, S.J. (2023). Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy\u2014A balancing act. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1307398"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-70-1-89","article-title":"In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera","volume":"70","author":"Gimenez","year":"1989","journal-title":"J. Gen. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/infdis\/160.5.777","article-title":"Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte\/macrophage cell lines","volume":"160","author":"Krilov","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/imm.12541","article-title":"Contribution of Fc\u03b3 receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells","volume":"147","author":"Ramirez","year":"2016","journal-title":"Immunology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1128\/IAI.00533-16","article-title":"Neonatal Fc Receptor Regulation of Lung Immunoglobulin and CD103+ Dendritic Cells Confers Transient Susceptibility to Tuberculosis","volume":"84","author":"Vogelzang","year":"2016","journal-title":"Infect. Immun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood.2019001133","article-title":"FcRn augments induction of tissue factor activity by IgG-containing immune complexes","volume":"135","author":"Cines","year":"2020","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e20200359","DOI":"10.1084\/jem.20200359","article-title":"FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity","volume":"217","author":"Hubbard","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.3770","article-title":"IgG Fc domains that bind C1q but not effector Fc\u03b3 receptors delineate the importance of complement-mediated effector functions","volume":"18","author":"Lee","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/cdli.3.3.280-286.1996","article-title":"Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies","volume":"3","author":"Gimenez","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Mokhtary, P., Pourhashem, Z., Mehrizi, A.A., Sala, C., and Rappuoli, R. (2022). Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081861"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Brady, T., Cayatte, C., Roe, T.L., Speer, S.D., Ji, H., Machiesky, L., Zhang, T., Wilkins, D., Tuffy, K.M., and Kelly, E.J. (2023). Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1283120"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"van Erp, E.A., Luytjes, W., Ferwerda, G., and van Kasteren, P.B. (2019). Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00548"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences","volume":"169","author":"Woods","year":"2002","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4161\/mabs.1.5.9496","article-title":"Motavizumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"mAbs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Dekkers, G., Treffers, L., Plomp, R., Bentlage, A.E.H., de Boer, M., Koeleman, C.A.M., Lissenberg-Thunnissen, S.N., Visser, R., Brouwer, M., and Mok, J.Y. (2017). Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00877"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1073\/pnas.1402458111","article-title":"Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy","volume":"111","author":"Hiatt","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4161\/mabs.3.6.17922","article-title":"The impact of glycosylation on monoclonal antibody conformation and stability","volume":"3","author":"Zheng","year":"2011","journal-title":"mAbs"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kecse-Nagy, C., Szittner, Z., Papp, K., Hegyi, Z., Rovero, P., Migliorini, P., L\u00f3r\u00e1nd, V., Homolya, L., and Prechl, J. (2016). Characterization of NF-\u03baB Reporter U937 Cells and Their Application for the Detection of Inflammatory Immune-Complexes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156328"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","article-title":"Animal models of respiratory syncytial virus infection","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine"},{"key":"ref_131","first-page":"100629","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: A simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_132","unstructured":"(2024, May 26). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) Disease in Infants: Supplementary Systematic Review of Economic Evidence. Available online: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-statement-prevention-respiratory-syncytial-virus-disease-infants-supplementary-systematic-review-economic-evidence\/naci-appendix-2024-05-17.pdf."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1542\/hpeds.2024-007739","article-title":"Nirsevimab: The Hidden Costs","volume":"14","author":"Neumann","year":"2024","journal-title":"Hosp. Pediatr."},{"key":"ref_134","unstructured":"(2024, April 20). AAP News, Sanofi Raising Price of RSV Immunization Nirsevimab April 12, 2024. Available online: https:\/\/publications.aap.org\/aapnews\/news\/28657\/Sanofi-raising-price-of-RSV-immunization."},{"key":"ref_135","unstructured":"(2024, May 26). BEYFORTUS 50 mg sol inj ser Pr\u00e9remplie, Vidal. Available online: https:\/\/www.vidal.fr\/medicaments\/beyfortus-50-mg-sol-inj-ser-preremplie-242583.html."},{"key":"ref_136","unstructured":"(2023, October 10). Circuit de Prescription du Nirsevimab (BEYFORTUS \u00ae) ARS de Bretagne. Available online: https:\/\/www.bretagne.ars.sante.fr\/system\/files\/2023-09\/Presentation%20Dr%20Lefevre.pdf."},{"key":"ref_137","unstructured":"(2024, June 04). Sanofi senkt Preis f\u00fcr Beyfortus, Apotheke-Adhoc. 16 May 2024. Available online: https:\/\/www.apotheke-adhoc.de\/nachrichten\/detail\/pharmazie\/sanofi-senkt-preis-fuer-beyfortus\/."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Gebretekle, G.B., Yeung, M.W., Ximenes, R., Cernat, A., Simmons, A.E., Killikelly, A., Siu, W., Rafferty, E., Brousseau, N., and Tunis, M. (2024). Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants. medRxiv.","DOI":"10.1101\/2024.03.21.24304675"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:58:32Z","timestamp":1760111912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":138,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cimb46090617"],"URL":"https:\/\/doi.org\/10.3390\/cimb46090617","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}